ripretinib (Qinlock)

following a resubmission assessed under the end of life and orphan medicine process:

ripretinib (Qinlock®) is accepted for use within NHSScotland.

Indication under review: for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.

In a randomised, double-blind, phase III study, ripretinib significantly improved progression free survival compared with placebo in patients with advanced GIST who had received treatment with at least three prior kinase inhibitors.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.